NCT05576181View on ClinicalTrials.gov

Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

PHASE1UnknownINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 15, 2022

Primary Completion Date

January 22, 2025

Study Completion Date

July 22, 2025

Conditions
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Interventions
DRUG

ThisCART19A

ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.

DRUG

Fludarabine Oral Tablet

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

DRUG

VP-16

VP-16 is used for lymphodepletion.

PROCEDURE

HSCT

Hematological stem cell transplantation

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Fundamenta Therapeutics, Ltd.

INDUSTRY

NCT05576181 - Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter